* known pregnancy or breastfeeding * estimated glomerular filtration rate (egfr) \<30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). * history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). patients with a history of hypothyroidism receiving a stable dose of thyroid replacement therapy for at least 6 weeks, with a documented normal tsh (primary hypothyroidism) or free thyroxine (secondary or tertiary hypothyroidism) level at least 6 weeks after the last dose change will be considered eligible for enrollment. * known hypersensitivity to fenofibrate or fenofibric acid. * ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus * use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d * prisoners/incarcerated individuals * inability to read, write or no access to a smart phone, computer or tablet device * intubated patients.

* known pregnancy or breastfeeding * estimated glomerular filtration rate (egfr) \<30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). * history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). patients with a history of hypothyroidism receiving a stable dose of thyroid replacement therapy for at least 6 weeks, with a documented normal tsh (primary hypothyroidism) or free thyroxine (secondary or tertiary hypothyroidism) level at least 6 weeks after the last dose change will be considered eligible for enrollment. * known hypersensitivity to fenofibrate or fenofibric acid. * ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus * use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d * prisoners/incarcerated individuals * inability to read, write or no access to a smart phone, computer or tablet device * intubated patients.

known pregnancy or breastfeeding estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). patients with a history of hypothyroidism receiving a stable dose of thyroid replacement therapy for at least 6 weeks, with a documented normal tsh (primary hypothyroidism) or free thyroxine (secondary or tertiary hypothyroidism) level at least 6 weeks after the last dose change will be considered eligible for enrollment. known hypersensitivity to fenofibrate or fenofibric acid. ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d prisoners/incarcerated individuals inability to read, write or no access to a smart phone, computer or tablet device intubated patients.

known pregnancy or breastfeeding estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). patients with a history of hypothyroidism receiving a stable dose of thyroid replacement therapy for at least 6 weeks, with a documented normal tsh (primary hypothyroidism) or free thyroxine (secondary or tertiary hypothyroidism) level at least 6 weeks after the last dose change will be considered eligible for enrollment. known hypersensitivity to fenofibrate or fenofibric acid. ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d prisoners/incarcerated individuals inability to read, write or no access to a smart phone, computer or tablet device intubated patients.

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device - intubated patients.

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device - intubated patients.

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin or atorvastatin. for the latter 2 statins, patients taking doses >40 mg/d will be excluded - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin or atorvastatin. for the latter 2 statins, patients taking doses >40 mg/d will be excluded - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device